Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06756035
PHASE1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Sponsor: Context Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.

Official title: Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2025-03-31

Completion Date

2028-12

Last Updated

2025-07-31

Healthy Volunteers

No

Interventions

DRUG

CT-95

Weekly IV dosing

Locations (8)

Context Investigational Site

Denver, Colorado, United States

Context Investigational Site

Chicago, Illinois, United States

Context Investigational Site

Grand Rapids, Michigan, United States

Context Investigational Site

Hackensack, New Jersey, United States

Context Investigational Site

Philadelphia, Pennsylvania, United States

Context Investigational Site

Nashville, Tennessee, United States

Context Investigational Site

San Antonio, Texas, United States

Context Investigational Site

San Antonio, Texas, United States